Immune-Boosting drug aims to outsmart Hard-to-Treat blood cancers

NCT ID NCT06594445

Recruiting now Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This phase 1 trial tests a new drug called GTB-3650 for adults with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug is designed to connect natural killer cells—a type of immune cell—to cancer cells, helping the immune system attack the cancer. The study aims to find the safest dose and see if the drug can shrink tumors or slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GTB-3650 (a TriKE drug that links natural killer cells to cancer cells)
What this could lead to: If successful, this could provide a new treatment option for people with hard-to-treat myeloid cancers who cannot have a stem cell transplant.
What could go wrong: This is an early-phase dose-finding trial with a small number of participants. The drug may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes myeloid neoplasm therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES MYELOID MALIGNANCY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.